Ibrutinib, the first in class of BTK inhibitor, has improved the management of patients with chronic lymphocytic leukemia. Since ibrutinib can cause atrial fibrillation in 6-16% of cases, it is clinically relevant to identify patients at higher risk to develop atrial fibrillation. Comorbidities associated with a higher risk to develop atrial fibrillation were recapitulated in a scoring system. This model proved to be a valid prognostic tool both in a general chronic lymphocytic leukemia population (n=860) and in an ibrutinib-treated cohort (n=354). Patients with score≥5 harbored the highest risk of atrial fibrillation and should be carefully monitored during ibrutinib therapy.

A SCORING SYSTEM TO PREDICT THE RISK OF ATRIAL FIBRILLATION IN CHRONIC LYMPHOCYTIC LEUKEMIA

Visentin, A;Piazza, F;Semenzato, G;Trentin, L
2019

Abstract

Ibrutinib, the first in class of BTK inhibitor, has improved the management of patients with chronic lymphocytic leukemia. Since ibrutinib can cause atrial fibrillation in 6-16% of cases, it is clinically relevant to identify patients at higher risk to develop atrial fibrillation. Comorbidities associated with a higher risk to develop atrial fibrillation were recapitulated in a scoring system. This model proved to be a valid prognostic tool both in a general chronic lymphocytic leukemia population (n=860) and in an ibrutinib-treated cohort (n=354). Patients with score≥5 harbored the highest risk of atrial fibrillation and should be carefully monitored during ibrutinib therapy.
2019
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11577/3305212
Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 14
  • ???jsp.display-item.citation.isi??? 12
social impact